Einzeltreffer — DigiBib

Introduction: Ukraine has a high prevalence of co-occurring disorders (COD), defined as having both substance use (SUD) and psychiatric disorders. Major depressive disorder (MDD) is the most prevalent psychiatric disorder among people with SUD. People with COD experience poor health outcomes, and international agencies propose integrated COD care. In Ukraine, treatment for SUD is delivered in specialized substance use clinics, without providing any other medical services for comorbidities, including MDD. Here we present the protocol, along the with the preliminary results of the MEDIUM project, including observations over the first 6 months.

Methods: A cluster-randomized type-2 hybrid trial was conducted to integrate MDD treatment into specialty clinics providing opioid agonist therapies (OAT) in Ukraine. Twelve clinics in four regions underwent randomization to control (N = 1) vs experimental arms (N = 2) in each region. Clinicians at experimental sites received tele-education through modified project ECHO using a facilitated screening, evaluation, and treatment algorithm of depression, with or without financial incentives. Service-, patient- and provider-level data were collected for the analysis every 6 months for 24 months.

Preliminary Results: For service delivery outcomes, 4421 patients enrolled on OAT across all sites were assessed for MDD for screening (76.7%), evaluation with diagnosis (43.5%) and treatment (30.7%) for MDD; 13.8% continued treatment at least for 6 months. For patient-level outcomes, 1345 patients and 54 providers participated in serial surveys every six months.

Conclusion: This study will be the first to explore integrated COD care in Ukraine and generate evidence on effective service integration and delivery strategies for people with COD receiving treatment at substance use clinics with broader implications for Eastern Europe and Central Asia region.

Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Titel:	Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine.
Autor/in / Beteiligte Person:	Machavariani, E ; Bromberg, DJ ; Dumchev, K ; Dvoriak, S ; Zeziulin, O ; Morozova, O ; Esserman, D ; Pykalo, I ; Saichuk, N ; Ivasiy, R ; Haddad, MS ; Altice, FL
Link:	View record from ScienceDirect (Volltext)
Zeitschrift:	Contemporary clinical trials, Jg. 131 (2023-08-01), S. 107248
Veröffentlichung:	New York, N.Y. : Elsevier, c2005-, 2023
Medientyp:	academicJournal
ISSN:	1559-2030 (electronic)
DOI:	10.1016/j.cct.2023.107248
Schlagwort:	Humans Analgesics, Opioid therapeutic use Ukraine epidemiology Depressive Disorder, Major diagnosis Depressive Disorder, Major drug therapy Substance Abuse, Intravenous psychology Opioid-Related Disorders diagnosis Opioid-Related Disorders epidemiology Opioid-Related Disorders drug therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural Language: English [Contemp Clin Trials] 2023 Aug; Vol. 131, pp. 107248. <i>Date of Electronic Publication: </i>2023 May 30. MeSH Terms: Depressive Disorder, Major* / diagnosis ; Depressive Disorder, Major* / drug therapy ; Substance Abuse, Intravenous* / psychology ; Opioid-Related Disorders* / diagnosis ; Opioid-Related Disorders* / epidemiology ; Opioid-Related Disorders* / drug therapy ; Humans ; Analgesics, Opioid / therapeutic use ; Ukraine / epidemiology References: Arch Intern Med. 1998 Sep 14;158(16):1789-95. (PMID: 9738608) ; Drug Alcohol Depend. 2010 Jul 1;110(1-2):126-36. (PMID: 20347234) ; JAMA Psychiatry. 2021 Sep 1;78(9):979-993. (PMID: 34076676) ; Psychopharmacology (Berl). 2006 Aug;187(2):229-36. (PMID: 16710714) ; World Psychiatry. 2002 Feb;1(1):16-20. (PMID: 16946807) ; Drug Alcohol Depend. 2013 Jul 1;131(1-2):23-35. (PMID: 23490450) ; Public Health Rev. 2017 Dec 29;38:31. (PMID: 29450101) ; BMC Health Serv Res. 2019 Oct 24;19(1):749. (PMID: 31651302) ; Alcohol Clin Exp Res. 2017 Jun;41(6):1220-1227. (PMID: 28421616) ; Drug Alcohol Depend. 2019 Apr 1;197:78-82. (PMID: 30784952) ; Prog Neuropsychopharmacol Biol Psychiatry. 2023 Jan 10;120:110623. (PMID: 36029929) ; Milbank Q. 2004;82(4):581-629. (PMID: 15595944) ; J Affect Disord. 2020 Apr 1;266:288-304. (PMID: 32056890) ; Lancet. 2019 Oct 26;394(10208):1560-1579. (PMID: 31657732) ; CMAJ. 2016 Jun 14;188(9):E179. (PMID: 27160873) ; BMJ. 2019 Apr 9;365:l1476. (PMID: 30967483) ; Drug Alcohol Rev. 2018 Apr;37 Suppl 1:S285-S293. (PMID: 29168263) ; Lancet Public Health. 2022 May;7(5):e482-e484. (PMID: 35358424) ; Med Care. 1996 Mar;34(3):220-33. (PMID: 8628042) ; Int J Drug Policy. 2015 Jan;26(1):37-42. (PMID: 25304049) ; Hepatology. 2010 Sep;52(3):1124-33. (PMID: 20607688) ; Curr Psychiatry Rep. 2017 May;19(5):28. (PMID: 28425023) ; Lancet. 2010 Jul 31;376(9738):367-87. (PMID: 20650518) ; Implement Sci. 2017 Apr 4;12(1):44. (PMID: 28372587) ; Prim Care Companion J Clin Psychiatry. 2002 Feb;4(1):9-11. (PMID: 15014728) ; Drug Alcohol Depend. 2011 Jul 1;116(1-3):137-41. (PMID: 21257274) ; JAMA. 2013 Jan 23;309(4):347-8. (PMID: 23340633) ; Evid Based Med Public Health. 2016;2:. (PMID: 27066590) ; Int J Health Policy Manag. 2014 Jul 26;3(2):77-89. (PMID: 25114946) ; Evid Rep Technol Assess (Full Rep). 2008 Nov;(173):1-362. (PMID: 19408966) ; Lancet. 2010 Jul 31;376(9738):355-66. (PMID: 20650513) ; Lancet. 2018 Apr 7;391(10128):1357-1366. (PMID: 29477251) ; J Affect Disord. 2013 Jan 10;144(1-2):7-15. (PMID: 22963896) ; Int J Drug Policy. 2014 Jan;25(1):53-60. (PMID: 24113623) ; Int J Drug Policy. 2017 Nov;49:48-53. (PMID: 28957756) ; J Subst Abuse Treat. 2021 Feb;121:108164. (PMID: 33191004) ; Med Care. 2012 Mar;50(3):217-26. (PMID: 22310560) ; Drug Alcohol Depend. 2009 Jan 1;99(1-3):280-95. (PMID: 18929451) ; Soc Psychiatry Psychiatr Epidemiol. 2005 Sep;40(9):681-90. (PMID: 16160752) ; Curr Opin Psychiatry. 2008 Jan;21(1):14-8. (PMID: 18281835) ; J Appl Psychol. 2003 Aug;88(4):680-93. (PMID: 12940408) ; Drug Alcohol Depend. 2015 Mar 1;148:47-55. (PMID: 25620732) ; Int J Drug Policy. 2022 Mar;101:103570. (PMID: 34954493) ; Schizophr Bull. 1998;24(4):589-608. (PMID: 9853791) ; Drugs (Abingdon Engl). 2015;22(3):255-262. (PMID: 27087758) ; Braz J Psychiatry. 2021 Mar-Apr;43(2):189-202. (PMID: 32491040) ; J Telemed Telecare. 2012 Dec;18(8):481-4. (PMID: 23209269) ; Harm Reduct J. 2011 Dec 30;8:32. (PMID: 22208726) ; Lancet Psychiatry. 2022 Nov;9(11):852-854. (PMID: 36244353) ; Nat Rev Dis Primers. 2020 Jan 9;6(1):3. (PMID: 31919349) ; J Clin Med. 2021 Mar 22;10(6):. (PMID: 33810072) ; Implement Sci. 2016 Mar 10;11:33. (PMID: 27013464) ; AIDS Behav. 2008 Sep;12(5):789-95. (PMID: 18064554) ; Int J Drug Policy. 2017 Oct;48:44-53. (PMID: 28800420) ; Addict Sci Clin Pract. 2022 Nov 26;17(1):65. (PMID: 36435811) ; J Clin Med. 2020 Sep 26;9(10):. (PMID: 32993107) ; Cochrane Database Syst Rev. 2011 Aug 10;(8):CD004145. (PMID: 21833948) ; Syst Rev. 2022 Feb 5;11(1):21. (PMID: 35123556) ; J Subst Abuse Treat. 2015 Jul;54:29-36. (PMID: 25841703) Grant Information: F31 DA054861 United States DA NIDA NIH HHS; U01 DA045384 United States DA NIDA NIH HHS; UL1 TR001863 United States TR NCATS NIH HHS; R01 DA033679 United States DA NIDA NIH HHS; R01 DA045384 United States DA NIDA NIH HHS; R01 DA043125 United States DA NIDA NIH HHS Contributed Indexing: Keywords: Co-occurring disorders (COD); Depression; Implementation science; Opioid agonist therapies (OAT); Opioids; People who inject drugs (PWID); Ukraine Substance Nomenclature: 0 (Analgesics, Opioid) Entry Date(s): Date Created: 20230601 Date Completed: 20230724 Latest Revision: 20240307 Update Code: 20240307 PubMed Central ID: PMC10527419

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine.